Slide 1: Inogen, Inc. Overview
August 7, 2023 Inogen, Inc. Overview
Slide 2: Notice Regarding Forward-Looking Statements
Notice Regarding Forward-Looking Statements This presentation and the accompanying oral presentation (the “Presentation”) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections
Slide 3: Our Company and Purpose
Our Company and Purpose Inogen is a medical technology company. We are a global leader in portable oxygen therapy solutions for patients with chronic respiratory conditions. Our Purpose: Improving Lives through Respiratory Care © 2023 Inogen, Inc. All Rights Reserved. 3
Slide 4: Inogen enabling ambulatory Long-term O2 Therapy for COPD Today
Inogen enabling ambulatory Long-term O2 Therapy for COPD Today Long-term oxygen therapy has been shown to help COPD patients who have severely low blood oxygen1 Portable oxygen concentrators are alternatives to traditional portable systems such as compressed oxygen cylinders and were preferred by pa
Slide 5: Chronic Obstructive Lung Disease (COPD)
Chronic Obstructive Lung Disease (COPD) Global prevalence 10.3% on While tobacco smoke is average 1 the primary cause, 1 in 4 people with COPD have 292 – 392 million estimated never smoked 4 patients globally 1 1.3 million emergency 6th leading cause of death in room admissions in the the U.S. in 20
Slide 6: Inogen: A global market leader with high quality, innovative, evidence-based chronic respiratory care solutions
Inogen: A global market leader with high quality, innovative, evidence-based chronic respiratory care solutions Locations in Geographic Reach & 20+ Years COPD main Respiratory California, Ohio, Texas, Diverse Go-To-Market of leadership in Indications Netherlands, Czech Republic1 Strategy Portable O2
Slide 7: Evolving Inogen
Evolving Inogen Building foundational and scalable capabilities to drive sustainable growth and return to profitability in the mid-to-long term 2023 2023 is an inflection point Building foundational HME and MedTech Company in 2023 is anInogen that sets inflection up forpoint scalable capabilities wi
Slide 8: Opportunity to drive growth and long-term profitability
Opportunity to drive growth and long-term profitability 〉 Expansion into airway clearance with clinically differentiated offering, Physio Assist, and opportunity to maximize Patient Life Time Value 〉 Digital Health / Remote Patient Monitoring Investments to ↑ Patients Quality of Life (QoL) and ↓dise
Slide 9: Evolving Inogen
Evolving Inogen In Support of our Strategy to Address Larger Patient Opportunities 01 02 Grow the Core by Evolving the Enhance Performance through New Product Commercial Model Introductions & Market Development Drive commercial excellence and productivity in Collaborate with the Scientific Advisory
Slide 10: Evolving Inogen
Evolving Inogen In Support of our Strategy to Address Larger Patient Opportunities 03 04 Drive Operational Efficiency and Elevate Accelerate Growth by Evaluating Customer Experience Inorganic Opportunities Streamline and digitize processes to remove Continue to evaluate opportunities to expand frict
Slide 11: Optimized channel strategy to drive growth for Inogen and its partners
Optimized channel strategy to drive growth for Inogen and its partners Channel Strategy aligned with patient diagnosis, prescription & device acquisition journey Call Point: PRESCRIBER PRESCRIBER + HCPs / HMEs DIRECT to CONSUMER U.S. Inogen & HME Partners Inogen ROW Distributors and Home Care Provid
Slide 12: Market Opportunity for POCs
Market Opportunity for POCs Inogen Quantitative Research 2021 CMS Estimated Penetration of POCs1 Market Opportunities Patients on Oxygen (Top 2 Box Agreement)3 100% 10.4 Million Oxygen Patients in 90% 18% Patients on Oxygen3 Top 2 Box 30% 2016-2022 according to IQVIA2 ATTITUDES Scores 80% 〉 There is
Slide 13: Addressing Patient Needs Through Portfolio Strategy
Addressing Patient Needs Through Portfolio Strategy Restricted Activities of Daily Living Exacerbations Hospitalizations Mortality Overlapping patient populations Clinical & Health Economics benefit from oxygenation Multiple comorbidities in the same patient and / or ventilation and /
Slide 14: Innovation Pipeline
Innovation Pipeline Recent Launches and 2023 – 2026 Illustrative Global Portfolio Blueprint 2023 - 2024 2024 - 2026 〉 Launch of Rove 4 & 6 Recent Pipeline 〉 8 yr. Expected Service Life 〉 POC with Portable Non-Invasive POC 〉 POC with higher than 6 Setting Ventilation 〉 Cellular Connectivity 〉 Pulse O
Slide 15: Strategic Rationale
Strategic Rationale Shared purpose to improve the lives of respiratory patients Aligns with Inogen’s strategy and long- Provides a differentiated and clinically proven innovative term financial goals airway clearance technology with capital sales and desirable recurring revenue from disposables Leve
Slide 16: Revenue Overview
Revenue Overview Five-year Revenue CAGR of 8.6% through 2022 through four commercial channels 5 Year CAGR of 8.6% Revenue Breakdown Revenue ($M) (12 Months ended Dec 31, 2022) $400 $377.2 $358.1 $361.9 $358.0 $350 $308.5 Domestic B2B International B2B $300 $249.4 26.8% 22.8% $250 $200 8.6% CAGR $150
Slide 17: Selected Financials
Selected Financials Solid Balance Sheet and Cash Balance with opportunities to improve gross margin as supply visibility improves As of June 30, 2023 Gross Margin Profile Sales Gross Margin % Rental Gross Margin % Total Gross Margin % 60% Cash, cash equivalents & 57.4% $170.1M 50% 54.3% marketable s
Slide 18: Operating Discipline Goals
Operating Discipline Goals Seeking to drive operating margin improvement across various levers to improve Adjusted EBITDA Reduced operating Maintaining critical Lowering manufacturing expenses withwhile investments a goalclosely of materials pricing returningoperating managing to adjusted expenses w
Slide 19: Why Inogen?
Global market leader with high quality, innovative, chronic respiratory care oxygen therapy solutions Setting up for scaled growth in core COPD markets in US and Internationally; readying to expand patient populations served and indications in support of growth strategy Notable progress on the strat
Slide 20: Improving lives through respiratory care
Improving lives through respiratory care